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Bangalore, IndiaAbstractThis study aimed to determine the antibiotic susceptibility pattern of Staphylococcus aureus (SA) and the circulating clones in Bangalore, India.
Susceptibility testing was performed for all cases of SA infections in a tertiary-care hospital. Panton-Valentine leucocidin (PVL) encoding genes
were detected, and sequence type and spa type were determined. Out of the 92 collected strains, 52.2% were methicillin-resistant SA
(MRSA), isolated from community-acquired (CA) infections in 60.4% and hospital-acquired (HA) infections in 39.6%. S. aureus isolates
were also highly resistant to erythromycin (54.3%) and ciproﬂoxacin (70.6%) in methicillin-susceptible SA (MSSA) and MRSA, as well as in
CA and HA infections. MRSA were found to be signiﬁcantly more resistant to gentamicin (p <0.001), cotrimoxazole (p <0.001) and
ciproﬂoxacin (p 0.001) than MSSA, but no signiﬁcant difference was observed between CA- and HA-SA. ST217 appeared as a new
emerging and prevalent clone, but ST772 remained the predominant clone, all being PVL-positive isolates. Our study points out the high
prevalence of MRSA, even in the community, and the worrying increase of resistance to ciproﬂoxacin and erythromycin among CA-
MSSA. Emergence of clone ST217 is reported for the ﬁrst time in India.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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should be considered ﬁrst authorIntroductionMethicillin-resistant Staphylococcus aureus (MRSA) is one of the
most important causes of antibiotic-resistant healthcare-asso-
ciated infections worldwide. MRSA was initially associated with
hospital-acquired (HA) infections and since the 2000s with
community-acquired (CA) infections [1]. In Europe, the per-
centages of invasive MRSA extend from less than 5% inNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artiNorthern European countries to more than 25% in southern
and Eastern European countries [2]. In the US military health
system and over a period extending from 2005 to 2010, 54% of
cases of hospital-onset bacteremia were due to MRSA [3]. The
prevalence of CA-MRSA infections varies widely among coun-
tries [4]. In the United States, CA-MRSA is one of the most
common cause of skin and soft tissue infections (SSTIs) in pa-
tients from emergency departments, and the clone USA300
(ST8-SCCmec IV) is largely predominant [5]. In Europe, the
prevalence of CA-MRSA is much lower but is increasing,
especially in countries where the incidence of HA-MRSA is low,
such as Denmark or the Netherlands [6]. Many different CA-
MRSA clones are found, of which the ST80-SCCmec IV Euro-
pean clone is the most widely disseminated [6,7].
In India, the consumption of antibiotics is considerable, and
the overall rate of MRSA in clinical specimens is signiﬁcant. In aNew Microbe and New Infect 2015; 7: 15–20
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
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isolates were reported as MRSA [8]. These isolates were also
resistant to multiple antibiotics: over 80% were resistant to
penicillin, cotrimoxazole, ciproﬂoxacin, gentamicin, erythro-
mycin and tetracycline [8]. In a study carried out in the neonatal
intensive care unit in Amritsar, the rate of MRSA in blood
cultures was 57.3% [9]. In India, the rate of MRSA carriage in
the community is also high. Indeed, Chatterjee et al. [10]
showed that 3.89% of children of an Indian community setting
were MRSA carriers. In Delhi, 18.1% of healthy parents
attending a well-baby clinic were shown to be MRSA carriers
[11]. MRSA from India belong to a wide variety of clones, with
the following predominant sequence types (ST): ST22, ST772,
ST239 and ST30 [12,13].
In this work, we collected the clinical characteristics of 92
cases of S. aureus infections at St. John’s hospital in Bangalore
(Karnataka) and analysed bacteriologic characteristics and the
antibiotic resistance phenotype of the corresponding isolates in
order to determine the rate of MRSA in CA and HA infections
and the different circulating clones.Materials and methodsTABLE 1. Types of Staphylococcus aureus infections collected
in Bangalore between November 2011 and February 2012
Site CA infections HA infections Total, n (%)
Skin and soft tissue
infections
43 20 63 (68.5)
Bone and joint infections 10 1 11 (12.0)
Respiratory infections 5 8 13 (14.1)
Sepsis 2 2 4 (4.3)
Urinary tract infection 1 0 1 (1.0)
Total 61 31 92
CA, community acquired; HA, hospital acquired.Patients
Cases of S. aureus infections diagnosed at the St. John’s hospital
from November 2011 to February 2012 were collected. For
each case, a questionnaire was ﬁlled out by the physician in
charge of the patient including the patient’s sex, age and type of
infection: skin and soft tissue infection (SSTI), urinary tract
infection, respiratory infection, bone and joint infection and
sepsis. CA Staphylococcus aureus (SA) infection was deﬁned
according to the US Centers for Disease Control and Pre-
vention deﬁnition for CA-MRSA when patients did not meet
any of the following criteria: (a) isolation of SA more than 48
hours after hospital admission; (b) history of hospitalization,
surgery or dialysis within 1 year of the SA culture; and (c)
presence of an indwelling catheter or a percutaneous device at
the time of culture.
Identiﬁcation and susceptibility testing
S. aureus strains were isolated from chromogenic agar medium
(ChromAgar; BioMérieux, Marcy-L’Etoile, France). Gram
staining was performed; the presence of catalase, coagulase and
DNase was conﬁrmed, as described elsewhere [14]. Antimi-
crobial susceptibility testing was performed for erythromycin,
gentamicin, amikacin, tetracycline, chloramphenicol, cotrimox-
azole and ciproﬂoxacin with the disk diffusion method ac-
cording to recommendations of the Clinical Laboratory
Standard Institute [15] on Mueller-Hinton agar plates (Himedia,New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceMumbai, India) at 37°C. Methicillin resistance was tested using a
cefoxitin disk on Mueller-Hinton agar [16].
Molecular characterization
Genomic DNA was extracted from an overnight culture of cells
in brain–heart infusion broth by using a standard phenol–
chloroform procedure [17]. Detection of the Panton-Valentine
leukocidin (pvl) encoding genes was carried out by PCR as
previously described [18]. Multilocus sequence typing was
performed as previously described [19]. Consensus sequences
were assembled from both orientations and the allelic proﬁle
was matched using the Multi Locus Sequence Typing database
(http://www.mlst.net/). Staphylococcal protein A (Spa) typing
was performed according to the procedure of Shopsin et al.
[20]. Consensus sequences were matched from both forward
and reverse sequences, and the repeat units were identiﬁed
using the Ridom database (http://spa.ridom.de/).
Statistical analysis
Chi-square test and Fisher’s exact test were used for comparing
proportions. Conﬁdence intervals were calculated for pro-
portions to allow sampling error.
Ethics committee approval
The Rural Development Trust Hospital Ethical Committee
approved the study.ResultsPatient characteristics and types of infections
Over the study period, 92 S. aureus clinical isolates were
collected and further analysed. Patients’ median age was 43
years (range, 7 days to 91 years), and 16 patients were younger
than 18 (17.4%). Thirty-four patients (37.2%) were hospitalized
in medical units, 41 (44.6%) in surgical units and 17 (18.2%) in
intensive care units. Male/female sex ratio was 2.29. Most of the
cases comprised SSTIs (n = 63, 68.5%), bone and joint infections
(n = 11, 12.0%) and respiratory tract infections (n = 13, 14.1%)
(Table 1). Three patients had septic shock; one had a urinaryEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 15–20
nses/by-nc-nd/4.0/)
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(n = 61) and HA infections for 33.7% (n = 31).
Strain characteristics
The overall MRSA rate was 52.2% and the major associated
resistances of the 92 isolates concerned erythromycin (n = 50,
54.3%) and ciproﬂoxacin (n = 65,70.6%) (Table 2). The per-
centage of resistance to erythromycin was not signiﬁcantly
different between MSSA and MRSA. The percentage of resis-
tance to ciproﬂoxacin was extremely high for MRSA (n = 41,
85.4%) and also for MSSA (n = 24, 54.5%). MRSA were signif-
icantly more resistant to gentamicin (p <0.001), cotrimoxazole
(p <0.001) and ciproﬂoxacin (p 0.001) than MSSA (Table 2). Of
note, all the isolates were susceptible to vancomycin. MRSA
were detected in 47.5% (n = 29) of the CA infections and 61.3%
(n = 19) of the HA infections (p 0.27). A comparison of the
antibiotic resistance proﬁles of CA- vs. HA-MRSA and those of
CA- vs. HA-MSSA showed no signiﬁcant differences (Table 3).
Spa types STs were determined for all the 92 isolates.
Sequence type 772 was the most frequently detected ST
(n = 18, 19.6%), either in MRSA or MSSA isolates, either in CA
or HA infections (Table 4). Speciﬁc spa types differentiated
ST772 isolates as MSSA (t345 and t11383) or MRSA (t3387 and
t657) (data not shown); all were Panton-Valentine leucocidin
(PVL) positive. The second most prevalent ST was ST217,
detected in 13 isolates (14.1%), mostly in MRSA isolates
(n = 12) and in both CA and HA infections; all were PVL pos-
itive. Both major STs ST772 and ST217 were highly resistant to
erythromycin (50% and 69.2%, respectively) and ciproﬂoxacin
(83.3% and 76.9%, respectively). However, ST772 was signiﬁ-
cantly more resistant to cotrimoxazole (77.8%) than ST217
(15.4%, p 0.001). MRSA and MSSA were also detected in iso-
lates belonging to ST1208 and ST239, both in CA and HA in-
fections. ST22 was detected for MRSA isolates associated with
HA infections only. ST5, ST30 and ST291 were detected for
MSSA only, associated with HA and CA infections. ST1, ST7,
ST9, ST45, ST88, ST672, ST2371 and ST2849 were detected
for MSSA isolates associated with CA infections only.TABLE 2. Antibiotic resistance proﬁles of 92 isolates of Staphyloco
2012 in Bangalore
Antibiotic
S. aureus (95%)
(95% CI)
MSSA (44%)
(95% CI)
MRSA (48%)
(95% CI)
Penicillin 91.3 (91.2–91.4) 81.8 (70.4–93.2) 100
Oxacillin 52.2 (42–62.4) 0 100
Gentamicin 34.7 (25–44.4) 9.1 (0.6–17.6) 58.3 (44.4–72.2)
Tetracycline 19.6 (11.5–27.7) 15.9 (5.1–26.7) 22.9 (11–34.8)
Erythromycin 54.3 (44.1–64.5) 45.5 (30.8–60.2) 62.5 (48.8–76.2)
Chloramphenicol 3.3 (0–7) 2.3 (0–6.7) 4.2 (0–9.9)
Cotrimoxazole 40.2 (30.2–50.2) 20.5 (8.6–32.4) 58.3 (44.4–72.2)
Ciproﬂoxacin 70.6 (61.3–79.9) 54.5 (39.8–69.2) 85.4 (75.4–95.4)
CI, conﬁdence interval; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicilli
NA, not applicable.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiPVL encoding genes were detected in 49 of the 92 strains
(53.3%). The PVL positive strains were associated with either
HA (54.8%) or CA (52.5%) infections. However, PVL were
found to be signiﬁcantly more prevalent in MRSA isolates
(68.8%) than in MSSA isolates (36.4%, p <0.05).DiscussionIn this study, we showed that from a prospective analysis of 92
cases of S. aureus infections from Bangalore, the rate of MRSA
was 52.2%: in CA infections 47.5% and in HA infections 61.3%.
Most of the specimens were isolated from SSTI, which is a
major cause of S. aureus disease in the community as well as in
hospitalized patients. Previous studies performed in both
northern and southern India have reported rates of CA-MRSA
of 9.4% and 10.9%, r; however, another study in a rural area of
Andhra Pradesh showed a CA-MRSA prevalence of 64.7%
[21–23]. This is consistent with a study performed in and
around Bangalore, where Goud et al. [24] reported a rate of
MRSA nasal carriage of 72.7% in healthy individuals. CA-MRSA
emergence has been described from every continent, even
though prevalence varies considerably between different parts
of the world [25]. Hence, compared to European countries,
CA-MRSA infection rate is particularly high in India, as well as
the United States [4,26]. Besides CA-MRSA prevalence, we
conﬁrmed that the proportion of HA-MRSA was also important
in our study (61.3%; 70.7% in the Alvarez-Uria study [23]).
Resistance to erythromycin was observed in 54.3% of
S. aureus, with no signiﬁcant difference between MSSA and
MRSA or CA and HA isolates. Another study reports slightly
lower rates in a rural setting in India (41.4% of CA-SA and 38%
of HA-SA) [23]. However in Indian tertiary-care hospitals,
Anupurba et al. [8] reported that more than 80% of HA-MRSA
were resistant to erythromycin, and Kini et al. [27] found a
resistance rate to erythromycin of 67% and 83% in CA-MSSA
and CA-MRSA, respectively. When considering European
countries, data differ depending on the area. When only 2% andccus aureus collected between November 2011 and February
p, MSSA vs.
MRSA
CA S. aureus
(61%) (95% CI)
HA S. aureus
(31%) (95% CI)
p, CA S. aureus
vs. HA S. aureus
0.002 86.9 (78.4–95.4) 100 0.04
NA 47.5 (35–60) 61.3 (44.2–78.4) 0.27
<0.001 36.1 (24–48.2) 32.3 (15.8–48.8) 0.82
0.44 18.0 (8.4–27.6) 22.6 (7.9–37.3) 0.60
0.14 52.5 (40–65) 58.1 (40.7–75.5) 0.66
1.00 3.3 (0–7.8) 3.2 (0–9.4) 1.00
<0.001 37.7 (25.5–49.9) 45.2 (27.7–62.7) 0.51
0.001 67.2 (55.4–79) 77.4 (62.7–92.1) 0.34
n-resistant Staphylococcus aureus; CA, community acquired; HA, hospital acquired;
lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 15–20
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TABLE 3. Comparison of antibiotic resistance proﬁles of Staphylococcus aureus samples collected between November 2011 and
February 2012 in Bangalore
Antibiotic
CA MRSA (29%)
(95% CI)
HA MRSA (19%)
(95% CI)
p, CA MRSA
vs. HA MRSA
CA MSSA (32%)
(95% CI)
HA MSSA (12%)
(95% CI)
p, CA S. aureus
vs. HA S. aureus
Penicillin 100 100 NA 75.0 (60–90) 100 0.08
Gentamicin 69.0 (52.2–85.8) 42.1 (19.9–64.3) 0.08 6.3 (0–14.7) 8.3 (0–23.9) 1.00
Tetracycline 20.7 (6–35.4) 26.3 (6.5–46.1) 0.73 15.6 (3–28.2) 16.7 (0–37.8) 1.00
Erythromycin 62.1 (44.4–79.8) 63.1 (41.4–84.8) 1.00 43.8 (26.6–61) 41.7 (13.8–69.6) 1.00
Chloramphenicol 6.9 (0–16.1) 0 0.51 0 8.3 (0–23.9) 0.27
Cotrimoxazole 58.6 (40.7–76.5) 57.9 (35.7–80.1) 1.00 18.8 (5.3–32.3) 16.7 (0–37.8) 1.00
Ciproﬂoxacin 79.3 (64.6–94) 94.7 (84.6–100) 0.22 56.3 (39.1–73.5) 50 (21.7–78.3) 0.75
CI, conﬁdence interval; CA, community acquired; HA, hospital acquired; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus;
NA, not applicable.
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Netherlands and Germany, respectively, were resistant to
macrolides [28], Adaleti et al. [29] reported a prevalence of
54.6% of erythromycin-resistant S. aureus in a hospital in
Istanbul, Turkey. In France, 21.2% of MSSA and 46.3% of MRSA
were resistant to erythromycin according to national survey
networks reports in 2008 (Rapport d’activité ONERBA, 2009,
http://www.onerba.org/IMG/pdf/ONERBA_rap2009-10_CH6-
2.pdf). Increasing resistance to erythromycin is of great concern
because macrolides are useful in cases of intolerance to β-lac-
tams or resistance to methicillin and exert beneﬁcial antitoxin
effects.
Finally, we found a high overall resistance to ciproﬂoxacin
(70.6%). Although resistance to ﬂuoroquinolones has been
widely described among MRSA, we report here that MSSA, and
especially CA-MSSA, are also strikingly resistant (54.5% and
56.3%, respectively). Ciproﬂoxacin resistance in MSSA has been
rarely described except in India, where a nationwide study
reported a prevalence of 46.6% of MSSA resistant toTABLE 4. Sequence types (ST) and spa types of Staphylococcus aure
infection
Sequence type (n) spa type (n)
MSSA
n (%)
CA infectio
n (%)
ST772 (18) t11383 (1), t3387 (2), t345 (1), t657 (14) 2 (4.4) 2 (5.9)
ST217 (13) t852 (9), t11682(1), t5(1), fail (2) 1 (2.2) 0 (0)
ST239 (11) t037 (10), t852 (1) 2 (4.4) 1 (2.9)
ST1208 (8) t064 (3), t008 (1), t2658 (2), t304 (2) 5 (10.9) 4 (11.8)
ST30 (8) t021 (6), t4109 (1), t318 (1) 8 (17.4) 6 (17.6)
ST5 (8) t442 (7), t491 (1) 8 (17.4) 5 (14.7)
ST291 (5) t1149 (2), t3096 (1), t2313 (1), t937 (1) 5 (10.9) 4 (11.8)
ST22 (4) t852 (4) 0 (0) 0 (0)
ST2371 (3) t852 (3) 2 (4.4) 2 (5.9)
ST672 (2) t3841 (2) 2 (4.4) 2 (6.5)
ST7 (2) t091 (1), t1243 (1) 2 (4.4) 2 (5.9)
ST88 (1) t186 (1) 1 (2.2) 1 (2.9)
ST2849 (1) t878 (1) 1 (2.2) 1 (2.9)
ST121 (1) t159 (1) 1 (2.2) 0 (0)
ST689 (1) t91(1) 1 (2.2) 0 (0)
ST580 (1) t12355 (1) 1 (2.2) 0 (0)
ST3049 (1)
ST9 (1)
ST1 (2)
ST45 (1)
Fail (1),
t547 (1),
t127 (2),
t015 (1)
0 (0),
1 (2.6),
2 (5.1),
1 (5.1)
0 (0),
1 (2.9),
2 (5.9),
1 (2.9)
Total 46 34
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcu
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceciproﬂoxacin in tertiary-care centres [30]. In another study in
India, 48% of CA-MSSA isolated from children with CA bone
and joint infections were resistant to ciproﬂoxacin [27]. Be-
tween 2011 and 2012 in a rural hospital in Andhra Pradesh,
another area close to Bangalore, the rate of CA-MSSA resistant
to ciproﬂoxacin was 57.1% [23]. The increase of ciproﬂoxacin
resistance among MSSA has also been observed in other parts
of the world [31,32], but very few data are available. In France,
6.2% of MSSA were resistant to ﬂuoroquinolones in 2008
(Rapport d’activité ONERBA, 2009).
We characterized S. aureus isolates, which we found to
belong to a wide variety of STs. Indeed, the 92 analysed isolates
fell into 19 different STs, and MSSA isolates were the most
diverse. ST772 was the most predominant clone and was
detected in MSSA and MRSA associated with CA and HA in-
fections. Among MRSA isolates, ST772 was the predominant
clone, along with ST217, ST239, ST22 and ST1208. The
occurrence of ST772, ST22 and ST239 in India has already been
reported in global epidemiologic trials [12,33]. Subsequently,us isolates from Bangalore according to origin of acquisition of
MRSA
PVL genes
n, HA infection,
n (%) n (%)
CA infection,
n (%)
HA infection,
n (%)
0 (0) 16 (34.8) 11 (40.7) 5 (26.3) 18/18
1 (8.3) 12 (26.1) 8 (29.7) 4 (21.1) 13/13
1 (8.3) 9 (19.6) 5 (18.5) 4 (21.1) 0/11
1 (8.3) 3 (6.5) 1 (3.7) 2 (10.5) 0/8
2 (16.7) 0 (0) 0 (0) 0 (0) 8/8
3 (25.0) 0 (0) 0 (0) 0 (0) 2/8
1 (8.3) 0 (0) 0 (0) 0 (0) 0/5
0 (0) 4 (8.7) 0 (0) 4 (21.1) 4/4
0 (0) 1 (2.1) 1 (3.7) 0 (0) 3/3
0 (0) 0 (0) 0 (0) 0 (0) 0/2
0 (0) 0 (0) 0 (0) 0 (0) 0/2
0 (0) 0 (0) 0 (0) 0 (0) 0/1
0 (0) 0 (0) 0 (0) 0 (0) 0/1
1 (8.3) 0 (0) 0 (0) 0 (0) 1/1
1 (8.3) 0 (0) 0 (0) 0 (0) 0/1
1 (8.3) 0 (0) 0 (0) 0 (0) 0/1
0 (0),
0 (0),
0 (0),
0 (0)
1 (2.1),
0 (0),
0 (0),
0 (0)
1 (3.7),
0 (0),
0 (0),
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0/1
0/1
0/2
0/1
12 46 27 19 49/92
s aureus; CA, community acquired; HA, hospital acquired.
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replacing ST239 in Indian hospitals. ST772 has now been also
reported in England, Hong Kong, Germany, Abu Dhabi and
Ireland [33–35]. The second most frequent ST was ST217 and
was mainly detected in MRSA isolates, either CA or HA. In our
study, the MRSA strains belonging to the ST217 clone har-
boured a group I agr and a class B mec complex with a ccrA2B2
(type 2) ccr complex, consistent with a type IV SCCmec cassette
(data not shown), as previously described [36,37]. ST217 has
been identiﬁed as a single locus variant of epidemic MRSA-15
within CC22 [38], and it has been detected only rarely in
humans in Italy and Switzerland [36], as well as in one animal
[37]. The presence of ST217 has not yet been reported in India,
suggesting the emergence of this clone in this area. Finally, a
large diversity of other STs were characterized, some of them
being common to MRSA and MSSA (ST1208, ST239 and
ST291). ST1208, accounting for almost 12% of our isolates, was
reported as a novel clone in 2012 in India [12].
In conclusion, we collected 92 S. aureus isolated from CA
and HA infections in a tertiary-care hospital in Bangalore. A
worrying proportion of MSSA isolates was resistant to ﬂuo-
roquinolones, even among CA-MSSA. MRSA occurrence was
also important in both hospital and community settings, and
MRSA isolates were multidrug resistant. However, the
distinction between CA- and HA-MRSA is blurring because the
CA-MRSA resistance proﬁle is no longer signiﬁcantly different
from that of HA-MRSA. ST772 was the predominating clone, as
is usually reported in India these days. We report here the
emergence of ST217 in Bangalore in CA and HA infections,
with a high rate of resistance to erythromycin and ciproﬂox-
acin. This clone has rarely been detected elsewhere in the
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